STUDY OF COMPARATIVE PHARMACOKINETICS AND BIOEQUIVALENCE OF DRUGS AMLODIPINE + VALSARTAN AND EXFORGE®


如何引用文章

全文:

详细

Objective: Drug Amlodipine+Valsartan is safe and effective for comprehensive treatment of arterial hypertension patients taken combined therapy by prescription. The development of new fix drug combination amlodipine and valsartan will provide in the near future a significant reduction in the cost of treatment. The aim of this work was investigation of bioequivalence for a generic drug Amlodipine+Valsartan, film-coated tablets, 10 mg+160 mg (Polpharma SA, Poland) and Exforge®, film-coated tablets, 10 mg+160 mg (Novartis Pharma AG, Switzerland). Materials and methods: 58 healthy volunteers were enrolled in open label, randomized, two sequence, two treatment cross-over study. Drugs were administered in two periods with a 21-day washout period in-between. Blood samples were collected over a 72-hour period. Amlodipine and Valsartan were measured in plasma using an automated LC-MS/MS assay. Pharmacokinetic parameters were calculated by non-compartmental analyses approach to evaluate AUC0-t, AUC0-∞ and Cmax. ANOVA was performed on the ln-transformed data and the 90% Confidence Interval (CI) was determined. Bioequivalence will be concluded if the 90% CI falls within 80-125% for AUC0-t and Cmax. Results: 53 volunteers completed the study and were considered for the pharmacokinetic and statistical analyses. Descriptive safety data analyses were performed on all 58 subjects. 90%-CI for corrected GMEAN of test and reference ratio was 94.76-105.24% for AUC0-t and 92.78-108.79% for Cmax in the case of amlodipine; 94.93-119.61% for AUC0-t and 90.41-116.03% for Cmax in the case of valsartan. So all pharmacokinetic parameters met the acceptance criteria as the 90% CI were within 80.00-125.00%. Conclusion: This study showed that Amlodipine+Valsartan, film-coated tablets, 10 mg+160 mg (Polpharma SA, Poland) is bioequivalent to reference product Exforge®, film-coated tablets, 10 mg+160 mg (Novartis Pharma AG, Switzerland).

作者简介

A. Khokhlov

Road clinical hospital at Yaroslavl station JSC “Russian Railways”; “Yaroslavl medical University”

150047, Yaroslavl, Russian Federation; 150000, Yaroslavl, Russian Federation

A. Miroshnikov

ClinPharmInvest

150047, Yaroslavl, Russian Federation

A. Khokhlov

ClinPharmInvest

150047, Yaroslavl, Russian Federation

N. Pozdnyakov

ClinPharmInvest

150047, Yaroslavl, Russian Federation

E. Voronina

Road clinical hospital at Yaroslavl station JSC “Russian Railways”

150047, Yaroslavl, Russian Federation

S. Gerasimchuk

ClinPharmInvest

150047, Yaroslavl, Russian Federation

Yu. Rybachkova

ClinPharmInvest

150047, Yaroslavl, Russian Federation

K. Manko

AKRIKHIN

142450, Moscow region, Noginsk district, Staraya Kupavna, Russian Federation

E. Dubovik

AKRIKHIN

142450, Moscow region, Noginsk district, Staraya Kupavna, Russian Federation

参考

  1. Шуникова М.И., Хохлов А.Л., Соснин А.Ю. Сравнительная оценка органопротективных свойств фозиноприла, амлодипина и метопролола у больных артериальной гипертонией. Consilium Medicum. 2008; 10(11): 30-5.
  2. Шальнова С.А., Кукушкин С., Маношкина Е., Тимофеева Т. Артериальная гипертензия и приверженность терапии. Врач. 2009: 12: 39-42.
  3. Конради А.О. Ключевые достижения в комбинированной антигипертензивной терапии последних лет. АГ. 2012; 6: 491-6.
  4. Хохлов А.Л., Рыска М., Кукес В.Г. Теоретические и практические основы проведения исследований воспроизведенных лекарственных препаратов: монография. ООО Фотолайф. 2017: 227.
  5. Poldermans D., Glazes R., Kargiannis S., Wernsing M., Kaczor J., Chiang Y.T., Yen J., Gamboa R., Fomina I. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther. 2007; 29(2): 279-89.
  6. Destro M., Luckow A., Samson M., Kandra A., Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J. Am. Soc. Hypertens. 2008; 2(4): 294-302.
  7. Khokhlov A.L., Ryska M., Kukes V.G. Theoretical and practical bases of research of reproduced medicinal products: monograph. LLC Fotolajf, 2017; 227. (in Russian)
  8. Smith T.R., Philipp T., Vaisse B., Bakris G.L., Wernsing M., Yen J., Glazer R. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J. Clin. Hypertens. 2007; 9(5): 355-64.
  9. Public Assessment Report Decentralised Procedure, (Valsartan), Procedure No: UK/H/3444/001-4/DC, UK licenceNo:PL 34771/0019-22, MacleodsPharma UK Limited, Medicines and Healthcare products Regulatory Agency, 2012.
  10. Public Assessment Report Scientific discussion, Valsartan “Mylan”, 40 mg, 80 mg and 160 mg capsules, hard, Valsartan, Procedure No: DK/H/1613/001-003/DC, 2010.
  11. Public Assessment Report Scientific discussion, Valsartan Cristers, 40 mg, 80 mg and 160 mg film-coated tablets (Valsartan), FR/H/410/01-03/DC, Applicant: Substipharm, 2011.
  12. Spinola A.C. et al. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. Clin Ther. 2009. 31(9): 1992-2001.
  13. UK Public Assessment Report, Valsartan 40 mg film-coated tablets, Valsartan 80 mg film-coated tablets, Valsartan 160 mg film-coated tablets (valsartan), PL 20092/0045-7, Safeguarding public health, Medicines and Healthcare products Regulatory Agency, 2010.
  14. Carvalho M. et al. Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry. Biopharm Drug Dispos. 2001. 22(9): 383-90.
  15. Liu Y. et al. Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose,randomized, two-way crossover study in healthy Chinese male volunteers. Clin Ther. 2009; 31(4): 777-83.
  16. Setiawati E. et al. Bioequivalence Study of Two Amlodipine Tablet Formulations. Maj KedoktIndon. 2008; 58(2).
  17. Al-Tamimi J.J.I. Bioequivalence and Pharmacokinetics of Two Formulations of Amlodipine Tablets in Healthy Subjects. Iraqi J Pharm Sci. 2014; 23(1).

版权所有 © Eco-Vector, 2018


 


##common.cookie##